Newsletter | May 9, 2019

05.09.19 -- Biosimilar Trastuzumab Market: What You Need To Know

Featured Editorial
Analysis Of The Trastuzumab Biosimilar Market As Herceptin Exclusivity Nears An End
By Robert Browne, Fuld + Company

This article provides a look at the trastuzumab biosimilar competitive landscape, including future competitors, the expected order of market launches, and Genentech's defensive strategy, along with several key questions companies launching trastuzumab biosimilars may need to consider to be competitive.

Biosimilars vs. Interchangeable Biologics: Which Is A Distraction?
By Anna Rose Welch, editor, Biosimilar Development

I found myself puzzled, to say the least, by a recent editorial intriguingly entitled “Biosimilars Are A Distraction.” What I ended up reading were several questionable economic and clinical claims I feel are worth dissecting. 

Industry Insights
Sensitive And Reproducible SPR-Based Concentration And Ligand-Binding Analyses
White Paper | GE Healthcare Life Sciences

Surface plasmon resonance (SPR) assays are used across the life cycle of a biopharmaceutical, from target identification, through CQA determination, development, and ongoing quality control. This article focuses on concentration assays associated with late-stage development and biotherapeutic drug chemical manufacturing and control.

Standing Out In The Crowded Biopharmaceutical Contract Manufacturing Market
Webinar | ISR Reports

When CDMOs understand what motivates drug innovators to outsource, who is involved in the service provider selection decision, and which CDMO attributes have the greatest influence on CDMO selection, they are able to communicate what is unique about their offering to the right audience at the right time. 

Connect With Biosimilar Development: